Trump Tariffs on Pharmaceuticals Could Spike Costs 100% for Common Meds, Including Entresto to Keytruda
The Trump administration announced 100% tariffs on foreign-manufactured drugs, aiming to incentivize U.S. production. Companies like Pfizer and Johnson & Johnson are negotiating. Affected drugs include Entresto (Novartis), Keytruda (Merck), Lenvima (Eisai), and Ozempic/Wegovy (Novo Nordisk). Prices could double without deals.
How this was made
The 30-second read
Why it matters
If implemented, drug prices could double, affecting both consumers and pharma earnings.
Market read
New tariff policy introduces significant regulatory risk for multinational pharma companies.
What to watch
Potential exemptions, legal challenges, and the timeline for plant construction could mitigate immediate impact.
Background
The Trump administration announced a 100% tariff on brand‑name drugs manufactured outside the U.S., aiming to force reshoring.
Ticker impact
Pfizer is negotiating with the administration to avoid the 100% tariff on foreign‑manufactured drugs.
Downside pressure if tariffs are enforced.
Tariff would double price of imported drugs, raising costs for Pfizer's overseas supply chain.
Johnson & Johnson is also in talks to mitigate the new 100% tariff on overseas drug production.
Potential short‑term decline.
Higher import costs could compress profit margins.
Novartis manufactures Entresto abroad and could see its price double under the tariff.
Downward pressure on Novartis shares.
Tariff directly targets the drug’s foreign production.
Merck produces Keytruda in Ireland and faces a possible 100% tariff.
Negative impact on Merck stock.
Tariff would raise cost of a flagship oncology drug.
Novo Nordisk makes Ozempic/Wegovy in Denmark, subject to the new tariff.
Downward pressure on Novo Nordisk.
Tariff directly impacts a major revenue driver.
Market effects
Pharmaceutical sector faces cost‑inflation risk; may trigger supply‑chain reshoring.
U.S. drug manufacturers could gain advantage; foreign producers face headwinds.
Potential ripple effects on global drug pricing and healthcare costs.
Counterpoint
Tariff may spur faster domestic manufacturing, creating long‑term competitive advantage for U.S. firms.
Key entities
- governmentTrump administration
Announced the tariff policy.
- companyPfizer
Major pharma negotiating to avoid tariff.
- companyNovartis
Manufacturer of Entresto, subject to tariff.
